Cas cliniques de cancer du rein des JOUM 2010

25 mars 2011

Auteurs : Y. Neuzillet
Référence : Prog Urol, 2011, 21, S27, suppl. S2




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Patard J.J., Baumert H., Corréas J.M., Escudier B., Lang H., Long J.A., Neuzillet Y., Paparel P., Poissonnier L., Rioux-Leclercq N., Soulié M. Recommandations en Onco-Urologie 2010 : Cancer du rein Prog Urol 2010 ;  20 : S319-S339 [inter-ref]
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 2007 ;  356 : 115-124 [cross-ref]
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 2009 ;  27 : 3584-3590 [cross-ref]
Bellmunt J., Flodgren P., Roigas J., Oudard S. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment BJU Int 2009 ;  104 : 10-18 [cross-ref]
Rini B.I. Metastatic renal cell carcinoma:many treatment options, one patient J Clin Oncol 2009 ;  27 : 3225-3234 [cross-ref]
Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 2010 ;  66 : 357-371 [cross-ref]
Escudier B., Bellmunt J., Négrier S., Bajetta E., Melichar B., Bracarda S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 2010 ;  28 : 2144-2150 [cross-ref]
Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. AVOREN Trial investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 ;  370 : 2103-2111 [cross-ref]
Escudier B., Négrier S., Gravis G., Chevreau C., Delva R., Bay J.O., et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 4516.
Kumar R., Knick V.B., Rudolph S.K., Johnson J.H., Crosby R.M., Crouthamel M.C., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 2007 ;  6 : 2012-2021 [cross-ref]
Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma:results of a randomized phase III trial J Clin Oncol 2010 ;  28 : 1061-1068 [cross-ref]
Ljungberg B., Cowan N.C., Hanbury D.C., Hora M., Kuczyk M.A., Merseburger A.S., et al. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update Eur Urol 2010 ;  58 : 398-406 [cross-ref]
Audenet F., Rouprêt M., Méjean A. Cancer du rein et thérapies ciblées : controverses sur les prises en charge thérapeutiques Prog Urol 2009 ;  19 : 596-605 [inter-ref]
Thibault F., Rixe O., Meric J.B., Renard-Penna R., Boostan H., Mozer P., et al. Traitement néoadjuvant du cancer du rein Prog Urol 2008 ;  18 : 256-258 [inter-ref]
Karakiewicz P.I., Suardi N., Jeldres C., Audet P., Ghosn P., Patard J.J., et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi Eur Urol 2008 ;  53 : 845-848 [cross-ref]
Robert G., Gabbay G., Bram R., Wallerand H., Deminière C., Cornelis F., et al. Case study of the month Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma Eur Urol 2009 ;  55 : 1477-1480 [cross-ref]
Amin C., Wallen E., Pruthi R.S., Calvo B.F., Godley P.A., Rathmell W.K. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy Urology 2008 ;  72 : 864-868 [inter-ref]
Margulis V., Matin S.F., Tannir N., Tamboli P., Swanson D.A., Jonasch E., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol 2008 ;  180 : 94-98 [cross-ref]
Thomas A.A., Rini B.I., Lane B.R., Garcia J., Dreicer R., Klein E.A., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 2009 ;  181 : 518-523 [cross-ref]
Bex A., van der Veldt A.A., Blank C., van den Eertwegh A.J., Boven E., Horenblas S., et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery World J Urol 2009 ;  27 : 533-539 [cross-ref]
Jonasch E., Wood C.G., Matin S.F., Tu S.M., Pagliaro L.C., Corn P.G., et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 2009 ;  27 : 4076-4081 [cross-ref]
Cowey C.L., Amin C., Pruthi R.S., Wallen E.M., Nielsen M.E., Grigson G., et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 2010 ;  28 : 1502-1507 [cross-ref]
Shuch B., Riggs S.B., LaRochelle J.C., Kabbinavar F.F., Avakian R., Pantuck A.J., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int 2008 ;  102 : 692-696 [cross-ref]
Zini L., Perrotte P., Capitanio U., Jeldres C., Shariat S.F., Antebi E., et al. Radical versus partial nephrectomy: effect on overall and noncancer mortality Cancer 2009 ;  115 : 1465-1471 [cross-ref]
Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. bRECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial Lancet 2008 ;  372 : 449-456 [cross-ref]
Köstler W.J., Hejna M., Wenzel C., Zielinski M.L. Oral mucositis complicating chemotherapy and/or radiotherapy:options for prevention and treatment CA Cancer J Clin 2001 ;  51 : 290-315
Duran I., Siu L.L., Oza A.M., Chung T.B., Sturgeon J., Townsley C.A., et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 2006 ;  42 : 1875-1880 [cross-ref]
Lebret T., Neuzillet Y., Pignot G. La néphrectomie est-elle indispensable en cas de métastases ? Prog Urol 2010 ;  20 : S33-S37 [inter-ref]






© 2011 
Elsevier Masson SAS. Tous droits réservés.